The Journal of clinical endocrinology and metabolism · 2019
Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heinrich Daniel A, Adolf Christian, Holler Finn, Lechner Benjamin, Schneider Holger, Riester Anna, Nirschl Nina, Sturm Lisa, Wang Xiao, Ladurner Roland, Seidensticker Max, Bidlingmaier Martin, Beuschlein Felix, Reincke Martin
Аннотация
CONTEXT: Primary aldosteronism (PA) represents a secondary form of arterial hypertension that can be cured by surgery. Evidence of adrenal insufficiency (AI) was recently found in patients with PA who had undergone unilateral adrenalectomy (uADX).
OBJECTIVE: To study the incidence and long-term outcome of postoperative AI after uADX for PA.
DESIGN: Prospective registry study (August 2014 until the end of 2018).
SETTING: Tertiary referral center.
PATIENTS: One hundred consecutive patients undergoing uADX for PA were included. All patients underwent postoperative ACTH stimulation testing.
INTERVENTION: Postoperative ACTH stimulation testing to identify patients with AI.
MAIN OUTCOME MEASURES: Incidence of patients with postoperative AI and definition of long-term outcome.
RESULTS: Twenty-seven percent of patients developed postoperative AI. Of these, 48% had postoperative ACTH stimulation serum cortisol levels ≤13.5 µg/dL (severe AI); 52% were classified into the group with moderate AI (stimulated serum cortisol levels: 13.5 to 17 µg/dL). Patients with severe AI required significantly longer hydrocortisone replacement therapy than the moderate group (median [25th, 75th percentiles]: 353 [294, 476] days; 95% CI: 284 to 322 days; vs 74 [32, 293] days; 95% CI: 11 to 137 days; P = 0.016). One patient with severe AI was hospitalized for an acute adrenal crisis. With a cumulative follow-up of 14.5 years, this produced an incidence rate of 6.9 adrenal crises per 100 patient-years.
CONCLUSION: We suggest performing postoperative ACTH stimulation tests in all patients who undergo uADX for PA.
OBJECTIVE: To study the incidence and long-term outcome of postoperative AI after uADX for PA.
DESIGN: Prospective registry study (August 2014 until the end of 2018).
SETTING: Tertiary referral center.
PATIENTS: One hundred consecutive patients undergoing uADX for PA were included. All patients underwent postoperative ACTH stimulation testing.
INTERVENTION: Postoperative ACTH stimulation testing to identify patients with AI.
MAIN OUTCOME MEASURES: Incidence of patients with postoperative AI and definition of long-term outcome.
RESULTS: Twenty-seven percent of patients developed postoperative AI. Of these, 48% had postoperative ACTH stimulation serum cortisol levels ≤13.5 µg/dL (severe AI); 52% were classified into the group with moderate AI (stimulated serum cortisol levels: 13.5 to 17 µg/dL). Patients with severe AI required significantly longer hydrocortisone replacement therapy than the moderate group (median [25th, 75th percentiles]: 353 [294, 476] days; 95% CI: 284 to 322 days; vs 74 [32, 293] days; 95% CI: 11 to 137 days; P = 0.016). One patient with severe AI was hospitalized for an acute adrenal crisis. With a cumulative follow-up of 14.5 years, this produced an incidence rate of 6.9 adrenal crises per 100 patient-years.
CONCLUSION: We suggest performing postoperative ACTH stimulation tests in all patients who undergo uADX for PA.